BIOMAT Database Logo BIOMAT Database Logo

Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy. 2006

J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Division of Experimental Therapy, The Netherlands Cancer Institute, Plesmanlaan 121, Amsterdam, The Netherlands.

Benefit from chemotherapy treatment in breast cancer patients is determined by the molecular make-up of the tumour. In a retrospective analysis, we determined the molecular subtypes of breast cancer originally defined by expression microarrays by immunohistochemistry in tumours of patients who took part in a randomised study of adjuvant high-dose chemotherapy in breast cancer. In addition, the topoisomerase II alpha (TOP2A) amplification status was determined by fluorescence in situ hybridisation and chromogenic in situ hybridisation. 411 of the 753 tumours (55%) were classified as luminal-like, 137 (18%) as basal-like and 205 (27%) as human epithelial receptor type 2 (HER2) amplified. The basal-like tumours were defined as having no expression of ER and HER2; 98 of them did express epidermal growth factor receptor and/or cytokeratin 5/6. The luminal-like tumours had a significantly better recurrence free and overall survival than the other two groups. From the 194 HER2-positive tumours, 47 (24%) were shown to harbour an amplification of TOP2A. Patients with an HER2-amplified tumour randomised to the high-dose therapy arm did worse than those in the conventional treatment arm, possibly caused by the lower cumulative anthracycline dose in the high-dose arm. The tumours with a TOP2A amplification contributed hardly to this difference, suggesting that TOP2A amplification is not the cause of the steep dose-response curve for anthracyclines in breast cancer. Possibly, the difference of the cumulative dose of only 25% between the treatment arms was insufficient to yield a survival difference.

UI MeSH Term Description Entries
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009364 Neoplasm Recurrence, Local The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site. Local Neoplasm Recurrence,Local Neoplasm Recurrences,Locoregional Neoplasm Recurrence,Neoplasm Recurrence, Locoregional,Neoplasm Recurrences, Local,Recurrence, Local Neoplasm,Recurrence, Locoregional Neoplasm,Recurrences, Local Neoplasm,Locoregional Neoplasm Recurrences,Neoplasm Recurrences, Locoregional,Recurrences, Locoregional Neoplasm
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004250 DNA Topoisomerases, Type II DNA TOPOISOMERASES that catalyze ATP-dependent breakage of both strands of DNA, passage of the unbroken strands through the breaks, and rejoining of the broken strands. These enzymes bring about relaxation of the supercoiled DNA and resolution of a knotted circular DNA duplex. DNA Topoisomerase (ATP-Hydrolysing),DNA Topoisomerase II,DNA Topoisomerase II alpha,DNA Topoisomerase II beta,DNA Type 2 Topoisomerase,TOP2A Protein,TOP2B Protein,Topoisomerase II,Topoisomerase II alpha,Topoisomerase II beta,Type II DNA Topoisomerase,alpha, Topoisomerase II,beta, Topoisomerase II
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D005260 Female Females

Related Publications

J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
May 2009, Journal of the National Cancer Institute,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
February 2011, Journal of the National Cancer Institute,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Re: Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy.
December 2009, Journal of the National Cancer Institute,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
December 2007, Breast cancer research and treatment,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer.
October 1999, Genes, chromosomes & cancer,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer.
June 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Predictive value of molecular subtypes and APOBEC3G for adjuvant chemotherapy in urothelial bladder cancer.
March 2023, Cancer medicine,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Tumour topoisomerase II alpha protein expression and outcome after adjuvant dose-dense anthracycline-based chemotherapy.
January 2012, Pathology oncology research : POR,
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.
March 2003, European journal of cancer (Oxford, England : 1990),
J Hannemann, and P Kristel, and H van Tinteren, and M Bontenbal, and Q G C M van Hoesel, and W M Smit, and M A Nooij, and E E Voest, and E van der Wall, and P Hupperets, and E G E de Vries, and S Rodenhuis, and M J van de Vijver
Intensive Adjuvant Chemotherapy for Breast Cancer.
October 1999, Breast cancer (Tokyo, Japan),
Copied contents to your clipboard!